Glasgow’s DeepMatter signs India trials deal

Glasgow-based DeepMatter Group plc, the AIM-listed company focusing on digitizing chemistry, said it has signed a trials agreement with Aurigene Pharmaceutical Services Limited in Hyderabad, India, to supply its DigitalGlassware platform.

Aurigene is an independently managed subsidiary of Dr. Reddy’s Laboratories Ltd.

Aurigene Pharmaceutical Services is a fully integrated Contract Research, Development and Manufacturing Organization (CRO/CDMO) providing a wide range of services for small and large molecule,” said DeepMatter.

DeepMatter will provide its DigitalGlassware platform to Aurigene Pharmaceutical Services to help screen, develop and scale up chemistry procedures and to accelerate custom drug discovery and development projects.

“Aurigene Pharmaceutical Services seeks to evaluate the technology to find efficiency and productivity gains through deeper data insights via collated aggregated data streams to better understand difficult synthetic routes and to foster active data sharing capabilities.

“The technology will help scan every reaction parameter and accelerate failed reaction diagnostics.

“Through this project Aurigene Pharmaceutical Services reinforces its focus to provide faster and efficient chemistry services to its customers and thus accelerating the drug discovery and development process.”

DeepMatter CEO Mark Warne said: This paid for trials agreement is another positive step in our strategy to provide our DigitalGlassware platform to the major global Contract Research Organisations (CRO’s) where the ability to reproduce is paramount in order to accelerate the discovery of new drugs.”

Aurigene Pharmaceutical Services CEO Ravi Venkataraman said: Aurigene Pharmaceutical Services is committed to leveraging cutting edge technologies to accelerate drug discovery and development, and providing differentiated services to our clients to bring new medicines to market.

“Digital transformation leveraging Artificial Intelligence (AI)/Machine Learning (ML) tools is a key focus area and our collaboration with DeepMatter is one step towards faster patient centric innovation.”